ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Sunday, November 12, 2023

9:00AM-11:00AM: Abstract Number: 0024

Detection of Synovial Signatures in Peripheral Blood of Patients with Rheumatoid Arthritis via a Novel Blood-Based DNA Capture Assay

(0013–0039.5) Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 0605

Determining the ECG Cut-off Point in Systemic Lupus Erythematosus Patients Undergoing Hydroxychloroquine Therapy

(0582–0608) SLE – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0261

Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results

(0252–0282) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 0596

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in Systemic Lupus Erythematosus (SLE): Achievement of Sustained SRI(4), BICLA and Dual Responses over 48 Weeks

(0582–0608) SLE – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0502

Developing Electronic Health Record Algorithms to Accurately Identify Psoriatic Arthritis Patients

(0483–0509) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: PsA

9:00AM-11:00AM: Abstract Number: 0164

Development and Validation of a Virtual Musculoskeletal Examination Method for Disease Activity Assessment in Rheumatoid Arthritis Patients

(0155–0175) Health Services Research Poster I

9:00AM-11:00AM: Abstract Number: 0197

Development of a Chikungunya Arthritis Disease Activity Score

(0196–0228) Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 0303

Development of a Human Cytotoxic Myoinjury Model with CD8+ T Cells and Muscle Cells Differentiated from Human Induced Pluripotent Stem Cells

(0283–0307) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 0559

Development of Charlson Comorbidity Index (CCI) Comorbidities and CCI Score in Danish Nationwide Cohort of 3,178 Patients with Newly Diagnosed Systemic Lupus Erythematosus

(0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I

9:00AM-11:00AM: Abstract Number: 0549

Development of Customized Digital Cognitive Assessment Battery: A Pilot Use Case in SLE Patients

(0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I

9:00AM-11:00AM: Abstract Number: 0161

Differences and Similarities Between the EULAR/ASAS-EULAR Recommendations and National Recommendations for Treatment of Patients with Psoriatic Arthritis and Axial Spondyloarthritis Across Europe

(0155–0175) Health Services Research Poster I

9:00AM-11:00AM: Abstract Number: 0619

Different Definitions of Disease Severity, Progression and Outcomes in Systemic Sclerosis Associated Interstitial Lung Disease: A Systematic Literature Review

(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

9:00AM-11:00AM: Abstract Number: 0265

Differential and Combinatorial Mechanism of Action of Golimumab and Guselkumab in Ulcerative Colitis Induction Therapy: IL-23 Blockade Drives Restoration of Normal Epithelium and Mucosal Healing

(0252–0282) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 0008

Differential Induction of Anti-Muscarinic Type-3-Receptor Antibodies by Immunization with 4-Hydroxy-2-nonenal-Modified Ro60 in BALB/c Mice

(0001–0008) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 0062

Differential Metabolic Profiles, Activation and Circadian Dynamics in Rheumatoid Arthritis and Psoriatic Arthritis Circulatory Monocytes

(0040–0064) Innate Immunity Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].